Tag: Dupixent
Sanofi: FDA grants priority review to Dupixent for COPD – 02/23/2024 at 09:41
(AOF) – Sanofi announces that the FDA grants priority review to the biologics license application for Dupixent for the treatment of chronic obstructive pulmonary disease (COPD) with type 2 inflammation.…
Sanofi: New indication for Dupixent in Japan
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
US FDA approves Dupixent for treatment of young children with esophageal disease – 01/25/2024 at 8:34 p.m.
((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto)) The US health regulator has approved the use of Dupixent, the flagship drug of Regeneron REGN.O and Sanofi SASY.PA, to treat allergic…
US FDA approves Dupixent for treatment of young children with esophageal disease – 01/25/2024 at 9:42 p.m.
((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto)) (Added executive commentary to paragraph 7 and general information throughout) by Leroy Leo and Puyaan Singh The US health regulator has approved…
Sanofi: FDA approves Dupixent update
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Sanofi: positive results for Dupixent against chronic obstructive pulmonary disease
(AOF) – Dupixent “made it possible to significantly reduce exacerbations of COPD” or “chronic obstructive pulmonary disease” in the context of a second positive phase III trial: these results “help…
the National Financial Prosecutor’s Office is investigating price manipulation concerning Dupixent
The National Financial Prosecutor’s Office opened an investigation in March targeting the large French pharmaceutical group Sanofi for price manipulation, a judicial source reported on Tuesday, November 7, confirming information…
Sanofi: FDA grants priority review to Dupixent
AB Published on 09/26/2023 at 7:53 a.m. Photo credit © Sanofi Corporate (Boursier.com) — The United…
Sanofi: Sanofi’s Dupixent on track to treat smokers’ bronchitis
(BFM Bourse) – The pharmaceutical group presented positive results on Sunday in the treatment of chronic obstructive pulmonary disease at an international congress. Fitch, for its part, raised Sanofi’s credit…
Sanofi: Will present advances for Dupixent
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Sanofi: up sharply after positive Dupixent trial
(CercleFinance.com) – Sanofi gained almost 5% in Paris, taking advantage of its results on Dupixent and an analysis by Oddo which confirmed its outperformance rating, with an unchanged price target…
Sanofi: positive data for Dupixent in COPD – 03/23/2023 at 09:00
sanofi (photo credit: Adobe Stock / ) (CercleFinance.com) – Sanofi announces that its Dupixent could become the first biological drug against chronic obstructive pulmonary disease (COPD), after a pivotal phase…